Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC’s First Committee on Drugs to Review Astellas’ Hyperphosphatemia Treatment on February 24
February 14, 2012
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
- Delivery Price Settlement Rate Just 79.1% at End of December: MHLW
February 9, 2012
- Selection Process for Clinical Research Core Hospitals to Begin in Early March
February 9, 2012
- US FDA Warns against Risk of CDAD in Patients Taking PPIs
February 9, 2012
- Drug Discovery Support Organization Needed to Prevent “Decay” of Drug Industry: Mr Hachiyama
February 8, 2012
- Prime Minister Noda Asks Korosho to Study Simultaneous Revisions of Medical, Nursing Fees Every 3 Years
February 7, 2012
- Japan’s Cancer Registry System Lags Behind Other Developed Countries: Mr Umemura of DPJ
February 7, 2012
- Growing Concerns that Premium for New Drug Development May Violate Antimonopoly Act
February 6, 2012
- National, Rosai Hospitals to Enhance Relationship Aiming at Joint Purchasing in July
February 3, 2012
- MHLW to Strengthen Counterfeit Drug Control Creating Public-Private Council
February 3, 2012
- PAFSC's 2nd Committee on Drugs Recommends Approval for Kyowa Kirin's ATL Treatment
February 2, 2012
- Application Based on Data from Public Domain Recommended for Baktar, Flagyl: PAFSC Second Committee
February 2, 2012
- MHLW Presents Tougher Restrictions on Reimbursement of Vitamins
February 1, 2012
- DPJ’s PAL Subcommittee to Discuss Legal Handling of Drugs and Medical Devices
February 1, 2012
- CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
January 31, 2012
- PAFSC’s First Committee Recommends Designation of Pasireotide Pamoate as Orphan Drug
January 30, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…